7bcfb173-3654-42a1-8664-d0d074e4618c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.240
- PROTEIN_SECRETION+0.170
- MITOTIC_SPINDLE+0.130
- HEME_METABOLISM+0.090
- ESTROGEN_RESPONSE_LATE+0.060
- WNT_BETA_CATENIN_SIGNALING+0.040
- ESTROGEN_RESPONSE_EARLY+0.020
- P53_PATHWAY+0.020
- PANCREAS_BETA_CELLS+0.000
- PI3K_AKT_MTOR_SIGNALING-0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- ANGIOGENESIS-0.410
- MTORC1_SIGNALING-0.390
- MYC_TARGETS_V2-0.390
- OXIDATIVE_PHOSPHORYLATION-0.390
- ALLOGRAFT_REJECTION-0.380
- INTERFERON_GAMMA_RESPONSE-0.360
- MYC_TARGETS_V1-0.360
- KRAS_SIGNALING_UP-0.330
- IL6_JAK_STAT3_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475149 | — | — | 0.890 |
| 2 | TCGA-E2-A15G-01A-11R-A12D-07 | — | B | 0.859 |
| 3 | eb67b977-b299-4bbc-b3f6-25d516473405 | — | — | 0.843 |
| 4 | TCGA-E7-A6MF-01A-12R-A32O-07 | — | — | 0.837 |
| 5 | MDT-AP-3246 | Med | Medulloblastoma | 0.825 |
| 6 | MDT-AP-0576 | Med | Medulloblastoma | 0.824 |
| 7 | SRR35579813 | — | B | 0.823 |
| 8 | MDT-AP-2991 | Med | Medulloblastoma | 0.819 |
| 9 | 0357aa51-9436-4923-9b1e-eb22bdf647df | — | — | 0.818 |
| 10 | MDT-AP-1270 | Med | Medulloblastoma | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |